ADC Therapeutics (ADCT) News Today $2.13 +0.13 (+6.50%) (As of 12/17/2024 ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 Time Period ADC Therapeutics SA (NYSE:ADCT) Major Shareholder Purchases $304,000.00 in StockDecember 14, 2024 | insidertrades.comADC Therapeutics (NYSE:ADCT) Given "Buy" Rating at GuggenheimDecember 14, 2024 | americanbankingnews.comADC Therapeutics' (ADCT) Buy Rating Reiterated at HC WainwrightDecember 14, 2024 | americanbankingnews.comResearch Analysts Issue Forecasts for ADCT FY2024 EarningsDecember 14, 2024 | americanbankingnews.comRedmile Group, LLC Increases Stake in ADC Therapeutics SADecember 13, 2024 | gurufocus.comRedmile Group, Llc Acquires 100,000 Shares of ADC Therapeutics SA (NYSE:ADCT) StockADC Therapeutics SA (NYSE:ADCT - Get Free Report) major shareholder Redmile Group, Llc purchased 100,000 shares of the business's stock in a transaction on Wednesday, December 11th. The stock was bought at an average cost of $3.04 per share, with a total value of $304,000.00. Following the purchase, the insider now owns 13,145,712 shares in the company, valued at approximately $39,962,964.48. This represents a 0.77 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through this link. Large shareholders that own 10% or more of a company's shares are required to disclose their transactions with the SEC.December 13, 2024 | marketbeat.comAnalysts Set Expectations for ADCT FY2024 EarningsADC Therapeutics SA (NYSE:ADCT - Free Report) - Equities researchers at HC Wainwright issued their FY2024 earnings per share estimates for ADC Therapeutics in a report released on Wednesday, December 11th. HC Wainwright analyst R. Burns anticipates that the company will earn ($1.75) per share forDecember 13, 2024 | marketbeat.comADC Therapeutics announces data from LOTIS-7 Phase 1b open-label clinical trialDecember 12, 2024 | markets.businessinsider.comADC Therapeutics falls -8.9%December 12, 2024 | markets.businessinsider.comPromising Efficacy in LOTIS-7 Trial Boosts Buy Rating for ADC TherapeuticsDecember 12, 2024 | markets.businessinsider.comADC Therapeutics SA Common Shares (ADCT) Insider ActivityDecember 11, 2024 | nasdaq.comADC Therapeutics stock plunges 36% amid Zynlonta data releaseDecember 11, 2024 | msn.comADC Teeters on Trial DataDecember 11, 2024 | baystreet.caADC Therapeutics Announces Positive Initial Data from LOTIS-7 Clinical Trial Evaluating ZYNLONTA® in Combination with Bispecific Antibody in Patients with Relapsed/Refractory Diffuse Large B-cell LymphomaDecember 11, 2024 | prnewswire.comADC Therapeutics Announces The Lancet Haematology Publication of Data from Investigator-Initiated Trial Evaluating ZYNLONTA® in Combination with Rituximab to Treat Relapsed/Refractory Follicular LymphomaDecember 9, 2024 | prnewswire.comInsider Selling: ADC Therapeutics SA (NYSE:ADCT) Major Shareholder Sells 25,352 Shares of StockADC Therapeutics SA (NYSE:ADCT - Get Free Report) major shareholder Redmile Group, Llc sold 25,352 shares of the stock in a transaction dated Wednesday, December 4th. The shares were sold at an average price of $2.07, for a total value of $52,478.64. Following the completion of the sale, the insider now owns 15,566,731 shares of the company's stock, valued at approximately $32,223,133.17. This trade represents a 0.16 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Large shareholders that own at least 10% of a company's shares are required to disclose their sales and purchases with the SEC.December 6, 2024 | marketbeat.comADC Therapeutics to Provide Initial Data Update on LOTIS-7 Clinical TrialDecember 6, 2024 | prnewswire.comADC Therapeutics SA (NYSE:ADCT) Shares Bought by Redmile Group LLCRedmile Group LLC raised its holdings in ADC Therapeutics SA (NYSE:ADCT - Free Report) by 2.6% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 15,669,217 shares of the company's stock after acquiring an additionalDecember 5, 2024 | marketbeat.comADC Therapeutics Makes Grants to New Employees Under Inducement PlanDecember 2, 2024 | prnewswire.comShort Interest in ADC Therapeutics SA (NYSE:ADCT) Declines By 9.7%ADC Therapeutics SA (NYSE:ADCT - Get Free Report) was the target of a significant decrease in short interest during the month of October. As of October 31st, there was short interest totalling 3,170,000 shares, a decrease of 9.7% from the October 15th total of 3,510,000 shares. Based on an average daily volume of 355,600 shares, the short-interest ratio is currently 8.9 days.November 19, 2024 | marketbeat.comADC Therapeutics SA (NYSE:ADCT) Q3 2024 Earnings Call TranscriptNovember 12, 2024 | msn.comADC Therapeutics Highlights Q3 Advances and Strategic FocusNovember 10, 2024 | markets.businessinsider.comADC Therapeutics SA (ADCT) Q3 2024 Earnings Call TranscriptNovember 9, 2024 | seekingalpha.comStephens & Co. Initiates Coverage of ADC Therapeutics (ADCT) with Overweight RecommendationNovember 9, 2024 | msn.comADC Therapeutics SA (NYSE:ADCT) Given Average Recommendation of "Moderate Buy" by BrokeragesShares of ADC Therapeutics SA (NYSE:ADCT - Get Free Report) have been given an average recommendation of "Moderate Buy" by the six ratings firms that are covering the company, Marketbeat.com reports. One research analyst has rated the stock with a hold rating and five have assigned a buy rating tNovember 8, 2024 | marketbeat.comStephens Initiates Coverage on ADC Therapeutics (NYSE:ADCT)Stephens began coverage on shares of ADC Therapeutics in a research report on Friday. They set an "overweight" rating and a $6.00 target price for the company.November 8, 2024 | marketbeat.comADC Therapeutics Reports Third Quarter and Year-to-Date 2024 Financial Results and Provides Operational UpdateNovember 7, 2024 | prnewswire.comADC Therapeutics's Earnings: A PreviewNovember 6, 2024 | benzinga.comADC Therapeutics Announces Investigator-Initiated Study Abstracts Accepted for Presentation at the 66th ASH Annual MeetingNovember 5, 2024 | prnewswire.comADC Therapeutics to Present at November Investor ConferencesNovember 4, 2024 | prnewswire.comADC Therapeutics Makes Grants to New Employees Under Inducement PlanNovember 1, 2024 | prnewswire.comADC Therapeutics (ADCT) to Announce Earnings on ThursdayADC Therapeutics (NYSE:ADCT) will be releasing earnings before the market opens on Thursday, November 7, Zacks reports.November 1, 2024 | marketbeat.comADC Therapeutics to Host Third Quarter 2024 Financial Results Conference Call on November 7, 2024October 31, 2024 | prnewswire.comInstitutional investors own a significant stake of 32% in ADC Therapeutics SA (NYSE:ADCT)October 28, 2024 | finance.yahoo.comADC Therapeutics S.A.October 16, 2024 | wsj.comShort Interest in ADC Therapeutics SA (NYSE:ADCT) Increases By 13.4%ADC Therapeutics SA (NYSE:ADCT - Get Free Report) was the target of a significant increase in short interest in September. As of September 30th, there was short interest totalling 3,560,000 shares, an increase of 13.4% from the September 15th total of 3,140,000 shares. Based on an average daily trading volume, of 394,400 shares, the days-to-cover ratio is currently 9.0 days.October 15, 2024 | marketbeat.comADC Therapeutics Makes Grants to New Employees Under Inducement PlanOctober 1, 2024 | globenewswire.comAffinity Asset Advisors LLC Makes New Investment in ADC Therapeutics SA (NYSE:ADCT)Affinity Asset Advisors LLC bought a new position in shares of ADC Therapeutics SA (NYSE:ADCT - Free Report) in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor bought 474,744 shares of the company's stock, valSeptember 25, 2024 | marketbeat.com205,221 Shares in ADC Therapeutics SA (NYSE:ADCT) Bought by Bank of New York Mellon CorpBank of New York Mellon Corp acquired a new stake in ADC Therapeutics SA (NYSE:ADCT - Free Report) during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 205,221 shares of the company's stock, valued at approximatelySeptember 24, 2024 | marketbeat.comADC Therapeutics (NYSE:ADCT) Trading 0.5% Higher ADC Therapeutics (NYSE:ADCT) Stock Price Up 0.5%September 12, 2024 | marketbeat.comADC Therapeutics Makes Grants to New Employees Under Inducement PlanSeptember 3, 2024 | globenewswire.comADC Therapeutics to Present at Upcoming Investor ConferencesSeptember 3, 2024 | globenewswire.comADC Therapeutics SA (NYSE:ADCT) Sees Large Drop in Short InterestADC Therapeutics SA (NYSE:ADCT - Get Free Report) was the recipient of a large decrease in short interest in the month of July. As of July 31st, there was short interest totalling 3,000,000 shares, a decrease of 6.0% from the July 15th total of 3,190,000 shares. Based on an average daily volume of 756,400 shares, the days-to-cover ratio is currently 4.0 days.August 19, 2024 | marketbeat.comADC Therapeutics SA (NYSE:ADCT) to Post FY2024 Earnings of ($2.04) Per Share, Cantor Fitzgerald ForecastsADC Therapeutics SA (NYSE:ADCT - Free Report) - Investment analysts at Cantor Fitzgerald increased their FY2024 earnings per share (EPS) estimates for ADC Therapeutics in a research report issued to clients and investors on Wednesday, August 7th. Cantor Fitzgerald analyst E. Schmidt now anticipatAugust 9, 2024 | marketbeat.comRBC Capital Reaffirms Their Buy Rating on ADC Therapeutics (ADCT)August 8, 2024 | markets.businessinsider.comADC Therapeutics (NYSE:ADCT) Announces Quarterly Earnings Results, Beats Estimates By $0.06 EPSADC Therapeutics (NYSE:ADCT - Get Free Report) posted its quarterly earnings data on Tuesday. The company reported ($0.38) earnings per share for the quarter, topping the consensus estimate of ($0.44) by $0.06. The firm had revenue of $17.41 million for the quarter, compared to the consensus estimate of $19.06 million. During the same period in the prior year, the company earned ($0.58) EPS.August 7, 2024 | marketbeat.comADC Therapeutics (NYSE:ADCT) Receives "Outperform" Rating from Royal Bank of CanadaRoyal Bank of Canada restated an "outperform" rating and issued a $8.00 target price on shares of ADC Therapeutics in a report on Wednesday.August 7, 2024 | marketbeat.comBuy Rating Upheld for ADC Therapeutics SA Amidst Strong Financials and Promising Oncology PipelineAugust 7, 2024 | markets.businessinsider.comADC Therapeutics SA: ADC Therapeutics Reports Second Quarter 2024 Financial Results and Provides Operational UpdateAugust 6, 2024 | finanznachrichten.deADC Therapeutics Reports Second Quarter 2024 Financial Results and Provides Operational UpdateAugust 6, 2024 | globenewswire.com Get ADC Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ADCT and its competitors with MarketBeat's FREE daily newsletter. Email Address Forbes rich list released… #1 to be assassinated? (Ad)Elon Musk has just exposed the “energy grift” of America in a recent tweet to his platform, X. And people are slowly starting to wake up to the Deep State’s lies. To get the full details on the fake “energy crisis” of America, watch this now ADCT Media Mentions By Week ADCT Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ADCT News Sentiment▼0.610.71▲Average Medical News Sentiment ADCT News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ADCT Articles This Week▼202▲ADCT Articles Average Week Get ADC Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ADCT and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies AVXL News IMNM News KURA News KROS News TYRA News CRON News ERAS News EOLS News DNTH News RAPP News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NYSE:ADCT) was last updated on 12/18/2024 by MarketBeat.com Staff From Our PartnersTrump’s Secret Manhattan ProjectOn January 20, a whole new Manhattan Project is set to begin: Trump’s Manhattan Project. Folks, I just s...Banyan Hill Publishing | SponsoredHow this >10-cent coin is going to outperform Bitcoin Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredSeeing is believing… Today, I want to share all the details with you… and show you how to leverage this incredible wealth-building ...Porter & Company | SponsoredUncover the Top Gold Stock of the Bull MarketGold Stocks Are Surging—Is West Red Lake Gold Mines Your Next Profit Play?Huge Alerts | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowIt’s here. This is the moment we’ve been waiting for. The next 3-6 months in crypto will be absolutely life...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ADC Therapeutics SA Please log in to your account or sign up in order to add this asset to your watchlist. Share ADC Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ADCT Stock Alerts